Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
W. Busse (Madison, United States of America), J. Maspero (Buenos Aires, Argentina), C. Katelaris (Sydney, Australia), D. Saralaya (Bradford, United Kingdom), S. Guillonneau (Chilly-Mazarin, France), B. Zhang (Chilly-Mazarin, France), C. Taniou (Nanterre, France), H. Staudinger (Bridgewater, United States of America), J. Chao (Tarrytown, United States of America), N. Amin (Tarrytown, United States of America), G. Pirozzi (Bridgewater, United States of America), M. Ruddy (Tarrytown, United States of America), B. Akinlade (Tarrytown, United States of America), N. H. Graham (Tarrytown, United States of America), A. Teper (Bridgewater, United States of America), A. Khan (Chilly-Mazarin, France). Dupilumab improves SNOT-22 scores in asthma patients with chronic rhinosinusitis or nasal polypsosis (CRS/NP) in LIBERTY ASTHMA QUEST. 1125

Member's Comments

No comment yet.

Related content which might interest you: Dupilumab improves asthma-related patient reported outcomes in asthma patients with chronic rhinosinusitis or nasal polyposis (CRS/NP) in LIBERTY ASTHMA QUEST Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures Year: 2018 Dupilumab efficacy in asthma patients with comorbid chronic rhinosinusitis or nasal polyposis (CRS/NP) in LIBERTY ASTHMA QUEST Source: International Congress 2018 – Novel immunology-based therapies in asthma and COPD Year: 2018 Impact of severe exacerbations on lung function in dupilumab-treated patients: LIBERTY ASTHMA QUEST Source: Virtual Congress 2021 – Pearls in immunology, outcome studies and clinical trials in asthma, alpha-1 antitrypsin deficiency and COPD Year: 2021 Dupilumab improves all ACQ-5 individual items in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP) and asthma: results from a phase 2a trial Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Efficacy of dupilumab in patients with oral corticosteroid (OCS)-dependent, severe asthma with and without an allergic phenotype: phase 3 LIBERTY ASTHMA VENTURE Source: Virtual Congress 2021 – Asthma and COPD meets COVID-19: new diagnostic tools and results from clinical trials Year: 2021 Effects of Omalizumab treatment on nasal symptoms (SNOT score) in patients treated for severe asthma. Source: International Congress 2017 – Asthma management Year: 2017 Dupilumab improves mental health measures in patients with chronic rhinosinusitis and nasal polyposis (CRSwNP) Source: International Congress 2018 – Understanding the immunopathology that underlies airway obstructive diseases Year: 2018 Evaluation and control of allergic rhinitis in patients with asthma (CARINA) in Korea Source: Eur Respir J 2007; 30: Suppl. 51, 382s Year: 2007 Dupilumab improves patient-reported outcomes in chronic sinusitis with nasal polyps patients with comorbid asthma: Results from a phase 2a trial Source: International Congress 2016 – Best abstracts in asthma and COPD Year: 2016 Dupilumab shows rapid and sustained suppression of inflammatory biomarkers in asthma patients in LIBERTY ASTHMA QUEST Source: International Congress 2018 – Understanding the immunopathology that underlies airway obstructive diseases Year: 2018 The relationship between asthma symptom control scores and rhinosinusitis scores in difficult-to-treat asthma Source: Annual Congress 2008 - Understanding airway inflammation Year: 2008 Patient characteristics and treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in Canada Source: Virtual Congress 2021 – Clinical features and new biomarkers of asthma, COPD and chronic cough Year: 2021 SNOT-22 items and association with objective measures in dupilumab-treated patients with severe chronic rhinosinusitis with nasal polyps from SINUS-24 and SINUS-52 trials Source: Virtual Congress 2021 – Asthma and COPD meets COVID-19: new diagnostic tools and results from clinical trials Year: 2021 Quality of life, clinical symptoms and nasal obstruction in patients with allergic rhinitis Source: Eur Respir J 2003; 22: Suppl. 45, 418s Year: 2003 Eosinophilic phenotype classification of patients with asthma and/or COPD in NOVELTY Source: Virtual Congress 2021 – Biomarkers to phenotype asthma: prediction of exacerbations Year: 2021 Mepolizumab reduces nasal symptoms in asthmatic patients with chronic rhino-sinusitis and nasal polyposis: a 12 months real-life study Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Non-atopic severe asthma – is it really always non-atopic? The IDENTIFY Project Source: International Congress 2017 – Many faces of asthma assessment Year: 2017 Characteristics by physician-assigned severity of asthma, asthma+COPD and COPD patients in the NOVELTY study Source: International Congress 2019 – Clinical implications of asthma management Year: 2019 CAPTAIN: Improvements in airflow obstruction in patients with uncontrolled asthma Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021 Asthma control and exacerbation rate with omalizumab in Italian patients with severe allergic asthma: PROXIMA study Source: International Congress 2017 – Asthma management Year: 2017